BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35793115)

  • 1. Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier.
    Randolph GW; Sosa JA; Hao Y; Angell TE; Shonka DC; LiVolsi VA; Ladenson PW; Blevins TC; Duh QY; Ghossein R; Harrell M; Patel KN; Shanik MH; Traweek ST; Walsh PS; Yeh MW; Abdelhamid Ahmed AH; Ho AS; Wong RJ; Klopper JP; Huang J; Kennedy GC; Kloos RT; Sadow PM
    Thyroid; 2022 Sep; 32(9):1069-1076. PubMed ID: 35793115
    [No Abstract]   [Full Text] [Related]  

  • 2. Analytical Performance of a Gene Expression Classifier for Medullary Thyroid Carcinoma.
    Pankratz DG; Hu Z; Kim SY; Monroe RJ; Wong MG; Traweek ST; Kloos RT; Walsh PS; Kennedy GC
    Thyroid; 2016 Nov; 26(11):1573-1580. PubMed ID: 27605259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: an institutional experience.
    Lastra RR; Pramick MR; Crammer CJ; LiVolsi VA; Baloch ZW
    Cancer Cytopathol; 2014 Oct; 122(10):737-44. PubMed ID: 25123499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Genomic Alternative to Identify Medullary Thyroid Cancer Preoperatively in Thyroid Nodules with Indeterminate Cytology.
    Kloos RT; Monroe RJ; Traweek ST; Lanman RB; Kennedy GC
    Thyroid; 2016 Jun; 26(6):785-93. PubMed ID: 26992356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afirma Gene Sequencing Classifier Compared with Gene Expression Classifier in Indeterminate Thyroid Nodules.
    Endo M; Nabhan F; Porter K; Roll K; Shirley LA; Azaryan I; Tonkovich D; Perlick J; Ryan LE; Khawaja R; Meng S; Phay JE; Ringel MD; Sipos JA
    Thyroid; 2019 Aug; 29(8):1115-1124. PubMed ID: 31154940
    [No Abstract]   [Full Text] [Related]  

  • 6. Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules.
    Hu MI; Waguespack SG; Dosiou C; Ladenson PW; Livhits MJ; Wirth LJ; Sadow PM; Krane JF; Stack BC; Zafereo ME; Ali SZ; Weitzman SP; Hao Y; Babiarz JE; Kennedy GC; Kloos RT
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2198-2207. PubMed ID: 34009369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance of the Afirma genomic sequencing classifier versus gene expression classifier: An institutional experience.
    Wei S; Veloski C; Sharda P; Ehya H
    Cancer Cytopathol; 2019 Nov; 127(11):720-724. PubMed ID: 31536167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the performance of the Afirma gene expression classifier.
    Hang JF; Westra WH; Cooper DS; Ali SZ
    Cancer Cytopathol; 2017 Sep; 125(9):683-691. PubMed ID: 28544601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Noninvasive Follicular Variant of Papillary Thyroid Carcinoma and the Afirma Gene-Expression Classifier.
    Wong KS; Angell TE; Strickland KC; Alexander EK; Cibas ES; Krane JF; Barletta JA
    Thyroid; 2016 Jul; 26(7):911-5. PubMed ID: 27219469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thyroid nodule molecular profiling: The clinical utility of Afirma Xpression Atlas for nodules with Afirma Genomic Sequencing Classifier-suspicious results.
    Babazadeh NT; Sinclair TJ; Krishnamurthy V; Jin J; Heiden KB; Shin J; Berber E; Siperstein A
    Surgery; 2022 Jan; 171(1):155-159. PubMed ID: 34924179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of Afirma Gene Sequencing Classifier versus Gene Expression Classifier in thyroid nodules with indeterminate cytology.
    Yang Z; Zhang T; Layfield L; Esebua M
    J Am Soc Cytopathol; 2022; 11(2):74-78. PubMed ID: 34366280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
    Gortakowski M; Feghali K; Osakwe I
    Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
    [No Abstract]   [Full Text] [Related]  

  • 13. Repeat Fine Needle Aspiration Cytology Refines the Selection of Thyroid Nodules for Afirma Gene Expression Classifier Testing.
    Nishino M; Mateo R; Kilim H; Feldman A; Elliott A; Shen C; Hasselgren PO; Wang H; Hartzband P; Hennessey JV
    Thyroid; 2021 Aug; 31(8):1253-1263. PubMed ID: 33813868
    [No Abstract]   [Full Text] [Related]  

  • 14. Performance of a Genomic Sequencing Classifier for the Preoperative Diagnosis of Cytologically Indeterminate Thyroid Nodules.
    Patel KN; Angell TE; Babiarz J; Barth NM; Blevins T; Duh QY; Ghossein RA; Harrell RM; Huang J; Kennedy GC; Kim SY; Kloos RT; LiVolsi VA; Randolph GW; Sadow PM; Shanik MH; Sosa JA; Traweek ST; Walsh PS; Whitney D; Yeh MW; Ladenson PW
    JAMA Surg; 2018 Sep; 153(9):817-824. PubMed ID: 29799911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology.
    Zhu QL; Faquin WC; Samir AE
    AJR Am J Roentgenol; 2015 Oct; 205(4):861-5. PubMed ID: 26397337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Testing for miRNA, mRNA, and DNA on Fine-Needle Aspiration Improves the Preoperative Diagnosis of Thyroid Nodules With Indeterminate Cytology.
    Labourier E; Shifrin A; Busseniers AE; Lupo MA; Manganelli ML; Andruss B; Wylie D; Beaudenon-Huibregtse S
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2743-50. PubMed ID: 25965083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the Afirma Gene Expression Classifier Result on the Surgical Management of Thyroid Nodules with Category III/IV Cytology and Its Correlation with Surgical Outcome.
    Chaudhary S; Hou Y; Shen R; Hooda S; Li Z
    Acta Cytol; 2016; 60(3):205-10. PubMed ID: 27344463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of Afirma genomic sequencing classifier vs gene expression classifier in Bethesda category III thyroid nodules: An institutional experience.
    Zhang L; Smola B; Lew M; Pang J; Cantley R; Pantanowitz L; Heider A; Jing X
    Diagn Cytopathol; 2021 Aug; 49(8):921-927. PubMed ID: 34021740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The first Canadian experience with the Afirma® gene expression classifier test.
    Kay-Rivest E; Tibbo J; Bouhabel S; Tamilia M; Leboeuf R; Forest VI; Hier MP; Savoury L; Payne RJ
    J Otolaryngol Head Neck Surg; 2017 Apr; 46(1):25. PubMed ID: 28372589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Afirma Gene Expression Classifier with Gene Sequencing Classifier in indeterminate thyroid nodules: A single-institutional experience.
    Geng Y; Aguilar-Jakthong JS; Moatamed NA
    Cytopathology; 2021 Mar; 32(2):187-191. PubMed ID: 33010060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.